| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $3,313,809 | 1 | 2 |
Sells | $98,596,323 | 52 | 98 |
| BAKER G LEONARD JR | director | 1 | $3.31M | 0 | $0 | $3.31M |
| Robb Gary Charles | Chief Business Officer | 0 | $0 | 1 | $1.16M | $-1.16M |
| Park Kimberly | director | 0 | $0 | 1 | $3.27M | $-3.27M |
| Lyon Joseph Douglas | See Remarks | 0 | $0 | 7 | $3.56M | $-3.56M |
| WILSON JAMES N | director | 0 | $0 | 6 | $5.18M | $-5.18M |
| Vieira Roberto Wandenkolk | President, Oncology | 0 | $0 | 3 | $7.46M | $-7.46M |
| BELANOFF JOSEPH K | Chief Executive Officer | 0 | $0 | 6 | $10.38M | $-10.38M |
| Guyer William | Chief Development Officer | 0 | $0 | 13 | $13.11M | $-13.11M |
| MAHONEY DAVID L | director | 0 | $0 | 2 | $13.94M | $-13.94M |
| Mokari Atabak | Chief Financial Officer | 0 | $0 | 4 | $18.73M | $-18.73M |
| Maduck Sean | See Remarks | 0 | $0 | 12 | $24.47M | $-24.47M |
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly …
Over the last 12 months, insiders at Corcept Therapeutics Incorporated have bought $3.31M and sold $98.6M worth of Corcept Therapeutics Incorporated stock.
On average, over the past 5 years, insiders at Corcept Therapeutics Incorporated have bought $3.31M and sold $42.94M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BAKER G LEONARD JR (director) — $3.31M.
The last purchase of 100,000 shares for transaction amount of $3.31M was made by BAKER G LEONARD JR (director) on 2026‑03‑17.
| 2026-10-15 | Sale | WILSON JAMES N | director | 10,000 0.0094% | $114.81 | $1.15M | -23.15% | |
| 2026-10-02 | Sale | Maduck Sean | See Remarks | 24,587 0.0233% | $116.28 | $2.86M | -3.01% | |
| 2026-10-02 | Sale | Lyon Joseph Douglas | See Remarks | 9,190 0.0087% | $116.13 | $1.07M | -3.01% | |
| 2026-10-02 | Sale | Vieira Roberto Wandenkolk | President, Oncology | 8,333 0.0079% | $116.10 | $967,448 | -3.01% | |
| 2026-10-01 | Sale | Maduck Sean | See Remarks | 413 0.0004% | $115.54 | $47,717 | -0.57% | |
| 2026-10-01 | Sale | Lyon Joseph Douglas | See Remarks | 810 0.0008% | $115.40 | $93,473 | -0.57% | |
| 2026-09-16 | Sale | Vieira Roberto Wandenkolk | President, Oncology | 296 0.0002% | $100.82 | $29,843 | +2.67% | |
| 2026-09-15 | Sale | WILSON JAMES N | director | 10,000 0.0092% | $110.69 | $1.11M | +3.54% | |
| 2026-09-14 | Sale | Lyon Joseph Douglas | See Remarks | 10,000 0.0096% | $113.49 | $1.13M | +2.31% | |
| 2026-09-02 | Sale | Vieira Roberto Wandenkolk | President, Oncology | 58,333 0.0541% | $110.76 | $6.46M | +3.21% | |
| 2026-09-01 | Sale | Maduck Sean | See Remarks | 25,000 0.0233% | $114.43 | $2.86M | +0.43% | |
| 2026-08-26 | Sale | Park Kimberly | director | 26,685 0.0253% | $122.55 | $3.27M | -4.99% | |
| 2026-08-25 | Sale | Maduck Sean | See Remarks | 30,955 0.0291% | $125.58 | $3.89M | -7.84% | |
| 2026-08-18 | Sale | MAHONEY DAVID L | director | 103,606 0.096% | $118.25 | $12.25M | -3.15% | |
| 2026-08-17 | Sale | Robb Gary Charles | Chief Business Officer | 10,000 0.0094% | $116.26 | $1.16M | -2.07% | |
| 2026-08-14 | Sale | WILSON JAMES N | director | 10,000 0.0092% | $111.43 | $1.11M | +0.29% | |
| 2026-08-14 | Sale | Maduck Sean | See Remarks | 3,664 0.0035% | $114.49 | $419,491 | +0.29% | |
| 2026-08-10 | Sale | Maduck Sean | See Remarks | 1,031 0.001% | $114.52 | $118,068 | +0.02% | |
| 2026-08-10 | Sale | Guyer William | Chief Development Officer | 16,300 0.0154% | $113.43 | $1.85M | +0.02% | |
| 2026-08-04 | Sale | Guyer William | Chief Development Officer | 3,700 0.0035% | $113.12 | $418,562 | +3.83% |
| BAKER G LEONARD JR | director | 1146631 1.0607% | $93.94M | 41 | 5 | +21.66% |
| MAHONEY DAVID L | director | 1133539 1.0486% | $92.87M | 12 | 12 | +42.33% |
| WILSON JAMES N | director | 1054543 0.9755% | $86.4M | 4 | 34 | +50.45% |
| Robb Gary Charles | Chief Business Officer | 39716 0.0367% | $3.25M | 1 | 31 | +72.23% |
| ALTA BIOPHARMA PARTNERS II LP | 10 percent owner | 5484063 5.0732% | $449.31M | 2 | 0 | +16.86% |
| PENHOET EDWARD | 5484063 5.0732% | $449.31M | 1 | 0 | +78.79% | |
| SUTTER HILL VENTURES | 10 percent owner | 5217464 4.8266% | $427.47M | 6 | 0 | +59.94% |
| MARDUEL ALIX | 10 percent owner | 5043299 4.6655% | $413.2M | 3 | 0 | +59.16% |
| GAITHER JAMES C | 10 percent owner | 4338742 4.0137% | $355.47M | 5 | 0 | +56.17% |
| Speiser Michael L | 10 percent owner | 4338742 4.0137% | $355.47M | 1 | 0 | +13% |
| SCHATZBERG ALAN F | director, 10 percent owner | 2438749 2.2561% | $199.81M | 1 | 1 | +197.78% |
| YOUNGER WILLIAM H JR | 10 percent owner | 575066 0.532% | $47.12M | 6 | 0 | +59.94% |
| COXE TENCH | 10 percent owner | 360048 0.3331% | $29.5M | 6 | 0 | +59.94% |
| ANDERSON DAVID L | 10 percent owner | 289747 0.268% | $23.74M | 6 | 0 | +59.94% |
| COOK JOSEPH C JR | director | 241521 0.2234% | $19.79M | 18 | 1 | +61.71% |
| ANDERSSON ALLEN | director | 209694 0.194% | $17.18M | 46 | 8 | <0.0001% |
| Paperboy Ventures, LLC | director | 209694 0.194% | $17.18M | 46 | 6 | <0.0001% |
| Longitude Venture Partners L.P. | 10 percent owner | 180103 0.1666% | $14.76M | 3 | 16 | +27.2% |
| BRADBURY DANIEL | director | 177925 0.1646% | $14.58M | 4 | 12 | +44.97% |
| BIRD JEFFREY W | 10 percent owner | 126252 0.1168% | $10.34M | 6 | 0 | +59.94% |
| WHITE JAMES N | 10 percent owner | 121117 0.112% | $9.92M | 6 | 0 | +59.94% |
| ENRIGHT PATRICK G | director | 114675 0.1061% | $9.4M | 3 | 23 | +27.2% |
| SANDS GREGORY P | 10 percent owner | 109913 0.1017% | $9.01M | 7 | 1 | +49.03% |
| Harper James A | director | 57900 0.0536% | $4.74M | 6 | 0 | +81.34% |
| SWEET DAVID E | 10 percent owner | 18480 0.0171% | $1.51M | 6 | 0 | +59.94% |
| SHEEHAN ANDREW T | 10 percent owner | 18325 0.017% | $1.5M | 4 | 0 | +17.87% |
| TURNER JOSEPH L | director | 10000 0.0093% | $819,300.00 | 2 | 0 | <0.0001% |
| GALA RENEE D | director | 10000 0.0093% | $819,300.00 | 2 | 0 | <0.0001% |
| KURLAND FRED | Chief Financial Officer | 7500 0.0069% | $614,475.00 | 2 | 0 | +11.49% |
| Increased Positions | 183 | +31.99% | 7M | +8.51% |
| Decreased Positions | 259 | -45.28% | 8M | -10.21% |
| New Positions | 65 | New | 2M | New |
| Sold Out Positions | 100 | Sold Out | 2M | Sold Out |
| Total Postitions | 496 | -13.29% | 77M | -1.7% |
| Blackrock, Inc. | $460,227.00 | 11.47% | 12.05M | -482,959 | -3.85% | 2025-09-30 |
| Vanguard Group Inc | $364,316.00 | 9.08% | 9.54M | -143,521 | -1.48% | 2025-09-30 |
| Ingalls & Snyder Llc | $294,063.00 | 7.33% | 7.7M | -24,938 | -0.32% | 2025-09-30 |
| Renaissance Technologies Llc | $232,613.00 | 5.8% | 6.09M | -177,055 | -2.83% | 2025-09-30 |
| Parallel Advisors, Llc | $147,889.00 | 3.69% | 3.87M | +329 | +<0.01% | 2025-09-30 |
| State Street Corp | $113,469.00 | 2.83% | 2.97M | +2,813 | +0.1% | 2025-09-30 |
| Fmr Llc | $84,114.00 | 2.1% | 2.2M | +844,990 | +62.27% | 2025-09-30 |
| Geode Capital Management, Llc | $73,889.00 | 1.84% | 1.93M | +18,656 | +0.97% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $72,292.00 | 1.8% | 1.89M | -193,069 | -9.26% | 2025-09-30 |
| Aqr Capital Management Llc | $57,575.00 | 1.44% | 1.51M | +1M | +546.89% | 2025-09-30 |